FDA's Guide to Settling Drug Debates Without Drama
Published Date: 12/23/2025
Notice
Summary
The FDA just released final guidance to help drug companies and FDA staff settle scientific disagreements through formal dispute resolution and hearings. This update affects anyone involved in drug reviews under Section 505G and aims to make the process clearer and fairer. The guidance is effective now, helping save time and avoid costly delays in drug approvals.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Final 505G Dispute-Resolution Guidance Published
On December 23, 2025 the FDA announced final guidance titled "Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act." The guidance gives recommendations for industry and review staff about formal dispute resolution (FDR) and administrative hearings for scientific or medical disputes between CDER and eligible requestors or sponsors of drugs subject to a Final Order under section 505G.
Paperwork Reduction Act Exemption for 505G Filings
Under section 505G(o) the Paperwork Reduction Act (PRA) does not apply to collections of information made under section 505G, so clearance by OMB under the PRA is not required for these collections. The guidance also references existing OMB-approved collections (for example, OMB control numbers 0910-0340 and 0910-0001).
Scope Limits and Submission Conduct Clarified
The final guidance clarifies that its recommendations are limited to FDR under section 505G(b)(2)(A)(iv)(III) and 505G(b)(4)(D)(iii) and to hearings under section 505G(b)(3). FDA removed language that could imply submitting new information outside of, or during, FDR and discouraged eligible requestors or sponsors from actively engaging other FDA entities or pursuing other regulatory or legal pathways on the same matter at the same time.
Electronic-Only Submissions Required
The guidance implements section 505G(j), which requires that all submissions related to section 505G must be in electronic format. Entities participating in FDR or hearings under section 505G must prepare and submit required materials electronically.
Consolidated Hearings Allowed for Same Order
The guidance describes procedures for consolidated proceedings and notes that under section 505G(b)(3)(C)(ii) a single hearing may be conducted if more than one request is submitted with respect to the same administrative order. The guidance also outlines best practices for consolidated appeals as required by section 505G(l)(4).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Previous / Next Documents
Previous: 2025-23706 — Green Mountain Power Corporation; Notice of Application Accepted for Filing, Soliciting Comments, Motions To Intervene, and Protests
Green Mountain Power wants to extend the licenses for two hydroelectric projects on Otter Creek in Vermont. This means they can keep running these power plants longer without changing how much electricity they produce. If you live nearby or care about the environment, you have until January 20, 2026, to share your thoughts or get involved before any decisions are made.
Next: 2025-23708 — International Product Change-Priority Mail Express International, Priority Mail International & First-Class Package International Service Agreements
The Postal Service is updating its international shipping deals by adding new contracts for Priority Mail Express International, Priority Mail International, and First-Class Package International Service. These changes affect businesses and customers who use these services, aiming to improve options and pricing. The updates were filed on December 16, 2025, and are now under review, so expect fresh shipping choices soon!